TY  - JOUR
AU  - Koerber, Stefan A
TI  - Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor.
JO  - PET clinics
VL  - 18
IS  - 3
SN  - 1556-8598
CY  - Orlando, Fla. [u.a.]
PB  - Elsevier
M1  - DKFZ-2023-00865
SP  - 369-380
PY  - 2023
N1  - #LA:E050# / 2023 Jul;18(3):369-380
AB  - Computed tomography (CT), MR imaging, and PET with fluorodeoxyglucose F18/CT are commonly used for radiation therapy planning; however, issues including precise nodal staging on CT or false positive results on PET/CT limit their usability. Clinical trials using fibroblast activation protein ligands for additional imaging have provided promising results regarding staging and target volume delineation-particularly suitable for sarcoma, some gastrointestinal tumors, head and neck tumors, and lung and pancreatic cancer. Although further prospective trials are necessary to identify clinical settings for its application in radiation oncology, fibroblast activation protein inhibitor PET/CT indisputably represents an excellent opportunity for assisting radiotherapy planning.
KW  - FAPI-PET/CT (Other)
KW  - Oncologic management (Other)
KW  - Radiation oncology (Other)
KW  - Treatment planning (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37117122
DO  - DOI:10.1016/j.cpet.2023.03.003
UR  - https://inrepo02.dkfz.de/record/275766
ER  -